DDInter704 DDInter997
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Ivacaftor
Everolimus {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Ivacaftor
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Modafinil
Modafinil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Everolimus {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inhibitors
Cytochrome P450 3A4 Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Amiodarone
Amiodarone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Everolimus {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Escitalopram
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Everolimus {u} (Compound) upregulates {v} (Gene) POR
POR {u} (Gene) interacts with {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ivacaftor
Everolimus {u} (Compound) causes {v} (Side Effect) Infestation
Infestation {u} (Side Effect) is caused by {v} (Compound) Mirabegron
Mirabegron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Everolimus (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Ivacaftor (Compound)
Everolimus (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Ivacaftor (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Modafinil (Compound) and Modafinil may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Everolimus (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Amiodarone (Compound) and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Everolimus (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Escitalopram (Compound) and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Everolimus (Compound) upregulates POR (Gene) and POR (Gene) interacts with CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ivacaftor (Compound)
Everolimus (Compound) causes Infestation (Side Effect) and Infestation (Side Effect) is caused by Mirabegron (Compound) and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ivacaftor